炎症性肠病患者接种SARS-CoV-2 mRNA疫苗后的不良事件
本研究评估了246名参与纵向疫苗登记的成人炎症性肠病(IBD)患者接种mRNA疫苗后的不良事件(AE)。总体上AE频率与普通人群相似,年轻患者和既往COVID-19者更常见,而接受生物制剂或小分子抑制剂治疗者AE较少。
要点
- IBD患者接种mRNA疫苗后AE频率与普通人群相似。
- 年轻患者和既往COVID-19者AE更常见。
- 接受生物制剂或小分子抑制剂者AE较少。
核心结论
- IBD患者接种mRNA疫苗后AE风险可能不增加,且在接受高级治疗时可能降低。
研究设计与样本
- 研究纳入246名参与纵向疫苗登记的成人IBD患者,评估mRNA疫苗接种后的不良事件。
主要发现
- AE频率总体上与普通人群报告相似。
- AE在年轻患者和既往COVID-19患者中更常见。
- 接受生物制剂或小分子抑制剂治疗者AE较少。
临床怎么用
- 可告知IBD患者接种mRNA疫苗后AE风险可能不增加,甚至可能降低,尤其是在接受高级治疗时。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Patients with immune-mediated inflammatory diseases such as inflammatory bowel disease (IBD) on immunosuppressive and biologic therapies were largely excluded from severe acute respiratory syndrome coronavirus-2 messenger RNA vaccine trials. METHODS: We evaluated adverse events (AE) after messenger RNA vaccination in 246 adults with IBD participating in a longitudinal vaccine registry. RESULTS: In general, AE frequency was similar to that reported in the general population. AEs were more common among younger patients and those with previous COVID-19. AEs were less common in individuals receiving advanced therapies with biologics or small-molecule inhibitors. DISCUSSION: Those with IBD and other immune-mediated inflammatory diseases can be reassured that the AE risk is likely not increased, and may be reduced, while on advanced therapies.
引用
- Botwin GJ, Li D, Figueiredo J, et al. Adverse Events After SARS-CoV-2 mRNA Vaccination Among Patients With Inflammatory Bowel Disease. Am J Gastroenterol. 2021. PMID: 34047304. doi:10.14309/ajg.0000000000001342
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。